Eosinophilic esophagitis (EE) is a chronic allergic disease of increasing prevalence diagnosed as an acid- independent esophageal eosinophilia of >15 per high power field. Esophageal epithelial proliferation, smooth muscle dysmotility, and esophageal strictures are EE associated features. Tissue remodeling with epithelial changes and subepithelial fibrosis occur in EE and involve TGF21, a pro-fibrotic molecule. However, the mechanisms for epithelial and smooth muscle changes are largely unclear;and the genetic factors for a more severe EE phenotype are unknown. There are no surrogate markers for EE. Children must undergo repeated invasive endoscopy with tissue biopsy for diagnosis and management. Our EE center provides the essential patient population and collaborative interactions for studying the mechanisms of EE and for understanding their impact on clinical disease.
Our first aim i s based on our preliminary studies demonstrating that Cripto-1, a new protein in EE, is increased in the esophageal epithelium of pediatric EE patients. We will use primary esophageal epithelial cells to understand how Cripto-1 increases esophageal epithelial cell proliferation and if Cripto-1 works with TGF2 family members. We will determine the expression of Cripto-1 in the esophagus of EE patients as compared with normal patients and define if Cripto-1 functions as a biomarker for EE.
Our second aim i s based on our current studies showing the novel findings that the smooth muscle in EE patients is infiltrated by mast cells that produce TGF21 and that TGF21 increases both esophageal smooth muscle cell contraction and phospholamban, a new protein in EE. We will use primary esophageal smooth muscle cells, EE patient myofibroblasts, gene silencing techniques, and a novel application of an in vitro contraction assay to delineate if TGF21 mediated contraction relies on phospholamban.
Our third aim i s based on our observation that a functional single nucleotide polymorphism (SNP) in the TGF21 promoter (C-509T) is associated with resolution of EE following swallowed topical corticosteroids. SNP analysis on EE patients and controls will be completed to define if the CC genotype associates with a therapy responsive phenotype and if the TT genotype associates with a more severe EE phenotype. Experiments using primary cells from EE patients of CC and TT genotype and chromatin immunoprecipitation for YY-1 will determine in vivo occupation of the TGF21 promoter and promoter activity in EE. These studies are designed to provide innovative techniques and new therapeutic targets for the understanding and care of EE patients.

Public Health Relevance

Eosinophilic esophagitis (EE) is an allergic disease that poses an increasing healthcare burden;diagnosis and management requires invasive endoscopy with biopsy in children. Associated disease features include epithelial proliferation, smooth muscle dysmotility with dysphagia, and esophageal strictures with fibrosis. The goal of this proposal is to elucidate novel mechanistic pathways in these processes in order to increase our understanding and improve our care of EE patients.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
1R01AI092135-01
Application #
8025819
Study Section
Hypersensitivity, Autoimmune, and Immune-mediated Diseases Study Section (HAI)
Program Officer
Minnicozzi, Michael
Project Start
2011-07-01
Project End
2016-06-30
Budget Start
2011-07-01
Budget End
2012-06-30
Support Year
1
Fiscal Year
2011
Total Cost
$386,250
Indirect Cost
Name
University of California San Diego
Department
Pediatrics
Type
Schools of Medicine
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Rajan, Jessica; Newbury, Robert O; Anilkumar, Arjun et al. (2016) Long-term assessment of esophageal remodeling in patients with pediatric eosinophilic esophagitis treated with topical corticosteroids. J Allergy Clin Immunol 137:147-56.e8
Rawson, Renee; Yang, Tom; Newbury, Robert O et al. (2016) TGF-β1-induced PAI-1 contributes to a profibrotic network in patients with eosinophilic esophagitis. J Allergy Clin Immunol 138:791-800.e4
Tkachenko, Eugene; Rawson, Renee; La, Elizabeth et al. (2016) Rigid substrate induces esophageal smooth muscle hypertrophy and eosinophilic esophagitis fibrotic gene expression. J Allergy Clin Immunol 137:1270-2.e1
Rawson, Renee; Anilkumar, Arjun; Newbury, Robert O et al. (2015) The TGFβ1 Promoter SNP C-509T and Food Sensitization Promote Esophageal Remodeling in Pediatric Eosinophilic Esophagitis. PLoS One 10:e0144651
Aceves, Seema S (2015) Eosinophilic esophagitis. Immunol Allergy Clin North Am 35:145-59
Beppu, Lisa; Yang, Tom; Luk, Michelle et al. (2015) MMPs-2 and -14 Are Elevated in Eosinophilic Esophagitis and Reduced Following Topical Corticosteroid Therapy. J Pediatr Gastroenterol Nutr 61:194-9
Doherty, Taylor A; Baum, Rachel; Newbury, Robert O et al. (2015) Group 2 innate lymphocytes (ILC2) are enriched in active eosinophilic esophagitis. J Allergy Clin Immunol 136:792-794.e3
Wen, Ting; Dellon, Evan S; Moawad, Fouad J et al. (2015) Transcriptome analysis of proton pump inhibitor-responsive esophageal eosinophilia reveals proton pump inhibitor-reversible allergic inflammation. J Allergy Clin Immunol 135:187-97
Beppu, Lisa Y; Anilkumar, Arjun A; Newbury, Robert O et al. (2014) TGF-β1-induced phospholamban expression alters esophageal smooth muscle cell contraction in patients with eosinophilic esophagitis. J Allergy Clin Immunol 134:1100-1107.e4
Aceves, Seema S (2014) Food allergy testing in eosinophilic esophagitis: what the gastroenterologist needs to know. Clin Gastroenterol Hepatol 12:1216-23

Showing the most recent 10 out of 20 publications